During the past several months together SG Austria and Nuvilex have been provided an opportunity to make new advances in the encapsulation material, production and resulting capsules, some of which will be destined for use in future company activities. Thus, the encapsulation technology platform and its resulting capsule can thus be viewed as a robust, implantable device which provides strength, support, protection and durability for live cells inside yet flexible enough to allow transplantation into animals and humans without giving rise to an immune response and therefore they alleviate the need for immunosuppression.Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, “Together with SG Austria, we are working to commercialize the Cell-in-a-Box ® technology platform through co-development activities and by establishing out-licensing deals with other companies that have potentially useful therapeutic cell systems that they would like to encapsulate and implant. Given the unique and advantageous properties of the Cell-in-a-Box ® technology, we anticipate seeing it incorporated into the cutting edge of medical treatments across a broad swath of unmet medical needs.” About Nuvilex Nuvilex, Inc. (OTCQB: NVLX) is an emerging international biotechnology provider of live, clinically useful, encapsulated cells and services for the research and medical communities. Through substantial effort, all aspects of our corporate activities alone and in concert with SG Austria are moving toward completion and a strong future together. Our company’s planned clinical offerings will include cancer, diabetes and other treatments using the company’s industry-leading cell and gene therapy expertise and cutting edge, live-cell encapsulation. Safe Harbor This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties including product demand, market competition, and Nuvilex’s ability to meet current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.